GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Aura Biosciences Inc.
Aura Biosciences is a biotech company developing targeted therapies for eye cancer. Its stock price is driven by news from its clinical trials. The chart reflects investor confidence in the potential of its unique viral platform for killing cancer cells.
Share prices of companies in the market segment - Cancer cure
Aura Biosciences is a biotech company developing a new class of targeted therapies for the treatment of ocular cancer, specifically uveal melanoma. We've classified it in the "Cancer Cure" segment. The chart below demonstrates the overall dynamics of this innovative yet risky biotech sector, where breakthrough treatments are being developed.
Broad Market Index - GURU.Markets
Aura Biosciences is an oncology company developing a new class of targeted therapy based on viral nanoparticles for the treatment of eye cancer. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how Aura Biosciences shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
AURA - Daily change in the company's share price Aura Biosciences Inc.
The daily price change of Aura Biosciences, an oncology company, reflects the high risks of the biotech sector. Change_co is an immediate reaction to news about clinical trials. This indicator is the basis for analysis of the cancer drug development sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer cure
Aura Biosciences, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with AURA, a company focused on eye cancer treatment, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Aura is a biopharmaceutical company developing targeted therapies for cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating Aura stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Aura Biosciences Inc.
For Aura Biosciences, year-over-year performance is a story about the development of targeted therapy for eye cancer. Its 12-month market cap depends entirely on progress in clinical trials of its unique virus-like particle platform. Every positive report from the FDA or a clinical trial is a fundamental driver of its value growth.
Annual dynamics of market capitalization of the market segment - Cancer cure
Aura Biosciences, Inc. is a clinical-stage biotechnology company developing a new class of targeted cancer therapies based on viral particles. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this cutting-edge field of oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aura Biosciences is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Aura Biosciences Inc.
The value of Aura, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its unique eye cancer therapy, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Aura Biosciences, Inc. is a biotechnology company developing a new class of targeted cancer therapies based on virus-like particles. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess how its unique platform, aimed at destroying cancer cells while sparing healthy tissue, is progressing in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aura Biosciences is a clinical-stage biotech company focused on treating eye cancer. Its shares move not with the market, but in anticipation of research news. The chart shows monthly performance, which is determined entirely by progress in drug development, not by general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Aura Biosciences Inc.
Aura Biosciences is a biotech company developing targeted therapies for eye cancer. Its weekly stock price, typical for this sector, is entirely dependent on clinical trial data. The chart reflects the high stakes involved in the fight against rare cancers.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Aura Biosciences, like the entire oncology biotech sector, is extremely volatile. Weekly stock fluctuations in this segment often reflect broader scientific breakthroughs or setbacks that impact investor interest in the entire sector. The chart illustrates this sectoral relationship.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aura Biosciences is an oncology biotech company. Its success depends on scientific breakthroughs. This chart clearly shows how often the company's shares move against the broader market in response to research data releases. How immune is it to overall market volatility?
Market capitalization of the company, segment and market as a whole
AURA - Market capitalization of the company Aura Biosciences Inc.
The Aura Biosciences chart tells the story of a new approach to eye cancer treatment. This biotech company's market cap reflects investors' faith in its virus-like particle technology, which enables targeted drug delivery to tumor cells. This is the curve of hope in ophthalmic oncology.
AURA - Share of the company's market capitalization Aura Biosciences Inc. within the market segment - Cancer cure
Aura Biosciences is a biotechnology company whose market share is based on its unique virus-like particle platform for targeted cancer cell killing, primarily in ophthalmology.
Market capitalization of the market segment - Cancer cure
Aura Biosciences is developing targeted cancer therapies. How big is this arena? The chart below shows the pulse of the cancer treatment sector. Its high volatility reflects both the enormous hopes for new breakthrough drugs and the high risks associated with their development and clinical trials.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Aura Biosciences chart shows how the market is valuing its unique approach to eye cancer treatment. The company's market cap is based on its virus-like particle platform, which delivers drugs precisely to tumors. This diagram illustrates how this highly targeted technology could open a new chapter in ophthalmic oncology.
Book value capitalization of the company, segment and market as a whole
AURA - Book value capitalization of the company Aura Biosciences Inc.
The book value of Aura Biosciences, an oncology company, is its material foundation: laboratories developing a unique virus-like particle platform, technology rights, and financial reserves for R&D. The chart below shows how the company built its physical and financial foundation to fight cancer.
AURA - Share of the company's book capitalization Aura Biosciences Inc. within the market segment - Cancer cure
Aura Biosciences is an oncology company whose tangible assets include laboratories and partner manufacturing facilities for the development of its unique virus-like particle platform for the treatment of eye cancer. The chart shows the share of this specialized biotech infrastructure controlled by this innovative company.
Market segment balance sheet capitalization - Cancer cure
Aura Biosciences is an oncology company. The pharmaceutical industry, as the chart shows, is both knowledge- and capital-intensive. Aura focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Aura Biosciences' assets include laboratories developing a unique virus-like particle platform for targeted cancer treatment. The chart shows how the company built its scientific and material foundation to bring this technology to market.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Aura Biosciences Inc.
Aura Biosciences is a biotech company. Its market valuation is a bet on its unique platform for targeted cancer treatment. The chart visualizes investors' hopes for their scientific breakthrough.
Market to book capitalization ratio in a market segment - Cancer cure
Aura Biosciences is a clinical-stage biotech company developing a new class of drugs for the treatment of eye cancer. Its valuation is based on the potential of its unique technology. The chart shows a high premium to its stock, reflecting investor expectations.
Market to book capitalization ratio for the market as a whole
Aura Biosciences is a clinical-stage biotech company developing a new class of cancer therapies using virus-like particles. Its current valuation, compared to the average, is a pure bet on the success of its scientific platform. Investors evaluate its potential to create breakthrough treatments, which is unrelated to its tangible assets.
Debts of the company, segment and market as a whole
AURA - Company debts Aura Biosciences Inc.
Aura Biosciences is developing a new class of targeted cancer therapy based on virus-like particles. This chart shows the financial position of the clinical-stage biotech company. It has no revenue and funds its expensive research by raising equity capital from investors.
Market segment debts - Cancer cure
Aura Biosciences is a clinical-stage biotech developing a new class of targeted therapies for cancer, beginning with ocular melanoma. This chart shows how its debt policy reflects its capital requirements to fund costly clinical trials of its innovative virus-like particle platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Aura Biosciences Inc.
Aura Biosciences is a biotech company developing a new treatment for eye cancer. Its technology is in clinical trials. This chart shows the extent to which the company is funding its expensive research with debt. It reflects its level of financial risk and its reliance on external capital until regulatory approval is obtained.
Market segment debt to market segment book capitalization - Cancer cure
Aura Biosciences is a clinical-stage biopharmaceutical company developing a new class of eye cancer therapies. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to fund its highly specialized and expensive research in this complex area of oncology.
Debt to book value of all companies in the market
Aura Biosciences is a biotech company developing targeted therapies for the treatment of eye cancer. This is a highly specialized area with high potential. Being in the clinical stage, the company is dependent on funding. This chart of total market debt demonstrates how favorable the investment climate is overall for such risky biotech projects.
P/E of the company, segment and market as a whole
P/E - Aura Biosciences Inc.
Aura Biosciences is a biotechnology company developing a new class of targeted therapy based on virus-like particles for the treatment of cancer, primarily ocular melanoma. This graph reflects investor expectations for this innovative platform. Its dynamics depend entirely on the results of clinical trials and the potential of the technology.
P/E of the market segment - Cancer cure
Aura Biosciences is a clinical-stage biotech company developing a new class of targeted cancer therapies using viral nanoparticles. Its lead candidate is aimed at treating ocular melanoma. This chart shows the average valuation for the oncology sector, reflecting investor expectations for innovative approaches to delivering drugs directly to tumors.
P/E of the market as a whole
Aura Biosciences is a biotech company developing a new class of targeted cancer therapy based on virus-like particles. Its valuation is a pure bet on the success of this unique technology. It is in no way tied to the general economic cycles illustrated by this chart. Its fate is decided in clinics and by regulators.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Aura Biosciences Inc.
Aura Biosciences is a biotechnology company developing a new class of targeted therapies based on virus-like particles for the treatment of cancer, primarily ocular melanoma. This graph reflects expectations for its unique technology. The company's valuation is a bet on the success of its clinical trials in oncology.
%20P%2FE%20Aura%20Biosciences%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Aura-Biosciences-Inc.&v=1772663011514 "Chart of the company's future (projected) P/E Aura Biosciences Inc.")
Future (projected) P/E of the market segment - Cancer cure
Aura Biosciences is a biotech company developing a new class of targeted cancer therapies based on virus-like particles. This chart reflects investor confidence in its unique scientific platform. Comparing its future revenue projections with the industry reveals how highly the market values its chances of developing a breakthrough cancer treatment.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772663011526 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Aura Biosciences is a clinical-stage biotechnology company developing a new class of targeted cancer therapy using viral nanoparticles. This is a cutting-edge scientific concept. This overall risk appetite curve is key to the company's ability to fund its innovative, yet risky, research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772663011546 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Aura Biosciences Inc.
Aura Biosciences, Inc. is a clinical-stage biotechnology company developing a new class of targeted cancer therapy using viral nanoparticles. Its financial performance reflects research expenses. Future revenue depends on the success of clinical trials and the commercialization of its innovative platform.
Profit of companies in the market segment - Cancer cure
Aura Biosciences is developing a new class of targeted therapies based on virus-like particles for the treatment of cancer, particularly ocular melanoma. This cancer treatment profitability chart reflects how innovative approaches targeting rare cancers can carve out niches and demonstrate enormous potential, attracting the attention of investors and major pharma companies.
Overall market profit
Aura Biosciences is a biotechnology company developing a new class of targeted therapy for cancer, specifically ocular melanoma. Its technology uses virus-like particles to deliver drugs directly to the tumor. This is an example of cutting-edge scientific research that could radically change approaches to cancer treatment.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Aura Biosciences Inc.
Aura Biosciences is developing a new class of targeted therapy for eye cancer based on viral nanoparticles. This chart shows the speculative expectations for this unique technology. Future revenue is entirely dependent on the success of clinical trials and regulatory approval.
%20profit%20of%20the%20company%20Aura%20Biosciences%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Aura-Biosciences-Inc.&v=1772663011676 "Graph of future (projected) profit of the company Aura Biosciences Inc.")
Future (predicted) profit of companies in the market segment - Cancer cure
Aura Biosciences is a biopharmaceutical company developing a new class of targeted cancer therapies using viral nanoparticles. This graph shows the projected profit trajectory for the biotech sector. This data allows us to assess the potential of this unique scientific platform to lead to breakthrough treatments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772663011704 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
The dynamics on this chart reflect expectations for a biotech company developing targeted therapies for cancer treatment. Aura Biosciences' profit forecast hinges on the results of clinical trials of its unique viral nanoparticle-based platform. This is a risky bet on an innovative approach to oncology.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772663011739 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Aura Biosciences Inc.
Aura Biosciences is an oncology company developing a new class of targeted therapies based on viral nanoparticles. It has no sales revenue. This chart shows a valuation based on the uniqueness and potential of its scientific platform. It is betting on success in clinical trials.
P/S market segment - Cancer cure
Aura Biosciences is a biotech company developing a new class of targeted cancer therapies using viral nanoparticles. Its valuation is based on the potential of its platform. This chart shows the average valuation in the oncology biotech industry, reflecting investor expectations for Aura's future revenue if its innovative treatment approach is successful.
P/S of the market as a whole
Aura Biosciences is a clinical-stage biotech company developing a new class of targeted therapies for cancer, beginning with ocular melanoma. Its technology uses virus-like particles. This graph, which displays the average revenue estimate for Aura Biosciences, highlights that its valuation is based on the uniqueness of its scientific approach and investor expectations.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Aura Biosciences Inc.
Aura Biosciences is a biotech company developing a new class of targeted cancer therapy using virus-like particles. Its lead candidate is designed to treat ocular melanoma. This chart reflects investor expectations for this innovative platform and the likelihood of its success in clinical trials for rare cancers.
%20P%2FS%20Aura%20Biosciences%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Aura-Biosciences-Inc.&v=1772663011906 "The graph of the company's future (projected) P/S Aura Biosciences Inc.")
Future (projected) P/S of the market segment - Cancer cure
Aura Biosciences is a biopharmaceutical company developing a new class of targeted cancer therapies based on virus-like particles. This chart compares market expectations for its future revenue with other companies working on cancer treatments. The valuation reflects investor confidence in its unique platform for treating ocular melanoma.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772663011912 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Aura Biosciences is a biotech company developing targeted therapies for ocular melanoma. Their approach is based on the use of viral nanoparticles. Success in clinical trials could create a new standard of treatment. This potential is part of the long-term expectations for biotech, as reflected in this graph.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772663011917 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Aura Biosciences Inc.
Aura Biosciences is a clinical-stage biopharmaceutical company developing a new class of targeted therapies for the treatment of cancer, primarily eye cancer. Currently, the company has no sales revenue. This chart will begin showing revenue after the commercialization of its unique technology.
Sales of companies in the market segment - Cancer cure
Aura Biosciences is a biotech company developing a new class of targeted therapies based on viral nanoparticles for the treatment of cancer, specifically ocular melanoma. This chart shows overall pharmaceutical sales, reflecting the search for innovative methods of delivering drugs directly to tumor cells to minimize side effects.
Overall market sales
Aura Biosciences is a clinical-stage biotechnology company developing a new class of targeted therapy for the treatment of eye cancer using virus-like particles. This overall economic activity chart for Aura is important from the perspective of investments. Funding for breakthrough oncology research depends on the overall health of the financial market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Aura Biosciences Inc.
Aura Biosciences is a clinical-stage oncology company developing a new class of targeted therapies based on virus-like particles for the treatment of cancer. This chart reflects analysts' speculative expectations for the success of its unique scientific platform and the potential of its drug candidates.
%20sales%20of%20the%20company%20Aura%20Biosciences%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Aura-Biosciences-Inc.&v=1772663011964 "Schedule of future (projected) sales of the company Aura Biosciences Inc.")
Future (projected) sales of companies in the market segment - Cancer cure
Aura Biosciences is a biotech company developing virus-like conjugates for targeted cancer treatment. This chart shows projected revenue for the entire biotech sector. While it reflects overall sentiment, for Aura, the key is the success of clinical trials for its innovative ocular melanoma treatment platform.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772663011969 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Aura Biosciences is a clinical-stage oncology company developing a new targeted cancer therapy. Its valuation and prospects depend on the results of clinical trials. This graph, reflecting economic sentiment, influences the investment climate in biotech, which affects Aura's ability to attract capital to continue its research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772663011991 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Aura Biosciences Inc.
Aura Biosciences is a clinical-stage biotech company developing a novel approach to cancer treatment. The chart for such a company illustrates not profits, but rather capital management efficiency. It shows how the company spends investor funds on research, striving to bring its promising developments to commercialization.
Market segment marginality - Cancer cure
Aura Biosciences is a clinical-stage biotech company developing a new class of cancer therapy that uses virus-like particles to target tumors. This chart reflects its operational structure, highlighting the significant research expenditures required to advance this innovative platform through clinical trials.
Market marginality as a whole
Aura Biosciences is a clinical-stage biopharmaceutical company developing a new class of targeted cancer therapies. Its future profitability depends on the success of its unique virus-like particle platform. This total market return chart highlights the high-risk, high-reward nature of biotechnology, where Aura strives to create breakthroughs in cancer treatment.
Employees in the company, segment and market as a whole
Number of employees in the company Aura Biosciences Inc.
Aura Biosciences is a biotech company developing a new class of targeted cancer therapies based on virus-like particles. This graph shows the team of scientists advancing their platform. The staff growth is directly related to progress in clinical trials, primarily for the treatment of ocular melanoma.
Share of the company's employees Aura Biosciences Inc. within the market segment - Cancer cure
This chart illustrates Aura Biosciences' focused approach. The company's oncology team is focused on developing a new class of targeted therapies based on virus-like particles for the treatment of eye cancer. This team of scientists is striving to create a drug capable of selectively destroying tumor cells while sparing healthy tissue.
Number of employees in the market segment - Cancer cure
Aura Biosciences is a biopharmaceutical company developing targeted therapies for ocular melanoma and other cancers. Its technology uses virus-like particles to deliver drugs precisely to the tumor. This graph illustrates how nanotechnology and virology are combining to create breakthrough treatments, requiring unique scientific talent.
Number of employees in the market as a whole
Aura Biosciences, Inc. is a biotechnology company developing targeted therapies for the treatment of eye cancer. Its revenue is entirely dependent on the success of its clinical programs. This general work schedule is unrelated to its mission to save sight and the lives of patients.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Aura Biosciences Inc. (AURA)
Aura Biosciences is a biotech company developing virus-like particles for targeted cancer treatment. This chart demonstrates the high valuation of its scientific platform. The astronomical market capitalization per research employee reflects investor expectations for its innovative approach, which could lead to a new class of drugs.
%20of%20the%20company%20Aura%20Biosciences%20Inc.%20(AURA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Aura-Biosciences-Inc.-AURA&v=1772663012075 "Chart of market capitalization per employee (in thousands of dollars) of the company Aura Biosciences Inc. (AURA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Aura Biosciences is developing a new class of targeted cancer therapy based on virus-like particles. In cutting-edge biotech, this figure reflects faith in a scientific breakthrough. The graph illustrates the enormous potential value the market sees in a unique platform capable of delivering drugs precisely to tumors.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772663012095 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Aura Biosciences, Inc. is a biotechnology company developing a new class of targeted cancer therapy using viral nanoparticles. This chart shows the high cost per employee typical for R&D companies. This cost is driven by the uniqueness of its scientific platform and the potential to create a new treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772663012106 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Aura Biosciences Inc. (AURA)
Aura Biosciences (AURA) is a clinical-stage biotech company developing cancer therapies (specifically, ocular melanoma) using virus-like particles. The company is not profitable. This chart shows the net loss (R&D costs) per scientist working on this innovative technology.
%20Chart%20Aura%20Biosciences%20Inc.%20(AURA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Aura-Biosciences-Inc.-AURA&v=1772663012113 "Company Profit Per Employee (in thousands of dollars) Chart Aura Biosciences Inc. (AURA)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Aura Biosciences is a biotech company developing a new class of cancer therapy—viral nanoparticles (VNPs)—that target tumors, such as eye cancer. This graph shows the loss per employee during the R&D phase. It serves as a benchmark for assessing how intensively Aura is investing in its scientists to validate this innovative drug delivery platform.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772663012120 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Aura Biosciences (AURA) is a biotech company developing cancer treatments (specifically, ocular melanoma) using viral nanoparticles. It is a clinical-stage company. This graph shows the loss per employee. It reflects the high cost of R&D: each scientist and physician involved in research requires a huge investment that has not yet generated any revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772663012139 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Aura Biosciences Inc. (AURA)
Aura Biosciences is an oncology company developing a new class of targeted therapies based on virus-like particles. This chart reflects the company's clinical-stage activity. Revenue per employee is virtually nonexistent, as all resources are focused on research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Aura-Biosciences-Inc.-AURA&v=1772663012142 "Sales chart per company employee Aura Biosciences Inc. (AURA)")
Sales per employee in the market segment - Cancer cure
Aura Biosciences is a biotech company developing targeted therapies for cancer (specifically, ocular melanoma) using virus-like particles. This chart shows the average revenue per employee in the segment. For a clinical-stage company, this is a benchmark for productivity.
Sales per employee for the market as a whole
Aura Biosciences is a clinical-stage biotech company specializing in cancer treatment (primarily ocular melanoma) using virus-like particles. They have no commercial products. This figure would be zero, as their team of scientists is focused on R&D and clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Aura Biosciences Inc. (AURA)
Aura Biosciences is a biotech company developing viral nanoparticles for targeted cancer treatment (specifically, ocular melanoma). The bearish sentiment seen in this chart reflects the risks of R&D. Bears are betting that this innovative technology will not prove effective or safe in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Aura-Biosciences-Inc.-AURA&v=1772663012212 "Short Shares Chart for the Company Aura Biosciences Inc. (AURA)")
Shares shorted by market segment - Cancer cure
Aura Biosciences is a biotech company developing "virus-like" particles for targeted delivery of chemotherapy into cancer cells (particularly for eye cancer). This chart reflects the general sentiment in the sector. It reflects the high level of investor skepticism toward oncology startups working with new, unproven platforms.
Shares shorted by the overall market
Aura Biosciences (AURA) is a biotech company developing treatments for eye cancer. It's a highly specialized clinical-stage company. This chart shows the overall level of risk aversion. When risk aversion rises, investors flee speculative biotechs, especially those focused on very niche markets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Aura Biosciences Inc. (AURA)
Aura Biosciences is a biotech company developing targeted therapy for eye cancer using viral nanoparticles. This is an extremely niche oncology field. This chart measures the level of speculative hope. It shows when the stock is "overheated" (overbought) on positive data or "oversold" amid delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Aura-Biosciences-Inc.-AURA&v=1772663012280 "RSI 14 indicator chart for the company's stock Aura Biosciences Inc. (AURA)")
RSI 14 Market Segment - Cancer cure
Aura Biosciences is a clinical-stage biotech company developing a new class of oncology drugs (VDCs). Their technology is aimed at treating eye cancer (choroidal melanoma) and other tumors. This chart reflects the overall sentiment in the oncology sector and helps assess how overheated this speculative biotech segment is.
RSI 14 for the overall market
Aura Biosciences (AURA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AURA (Aura Biosciences Inc.)
Aura Biosciences (AURA) is a biotech company developing viral nanoparticles for the targeted destruction of cancer cells, primarily ocular melanoma. This chart shows the average price target, reflecting analysts' confidence in this innovative platform and clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AURA-Aura-Biosciences-Inc.&v=1772663012366 "A chart showing analyst consensus forecasts for the expected stock price. AURA (Aura Biosciences Inc.)")
The difference between the consensus estimate and the actual stock price AURA (Aura Biosciences Inc.)
Aura Biosciences (AURA) is a biotech company developing a new class of drugs (VDC). Its technology uses viral particles to precisely deliver a poison directly to cancer cells (focusing on eye cancer). This chart shows the difference between the consensus estimate and the price, reflecting analysts' confidence in this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AURA-Aura-Biosciences-Inc.&v=1772663012379 "A chart showing the difference between the consensus forecast and the actual stock price. AURA (Aura Biosciences Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Aura Biosciences (AURA) is an oncology company developing a unique viral drug delivery platform (VDC) for targeted cancer treatment, beginning with eye cancer. This chart shows general expectations for the cancer treatment sector, reflecting experts' confidence in the success of this new drug delivery technology.
Analysts' consensus forecast for the overall market share price
Aura Biosciences is a biotech company developing virus-like particles (VDCs) for the targeted treatment of cancer, specifically ocular melanoma. This chart shows overall market sentiment. As an R&D company, Aura is sensitive to how overall risk appetite (sentiment) influences funding for their innovative, yet risky, oncology platform. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Aura Biosciences Inc.
Aura Biosciences is a biotech company working on viral oncology. Their platform (VDC) is a Trojan horse: a virus that delivers a toxic payload exclusively to cancer cells (their target is eye cancer). This graph is a pure R&D bet. It likely reflects the market's confidence in their viral delivery technology and their early clinical data in this niche.
AKIMA Market Segment Index - Cancer cure
Aura Biosciences (AURA) is a clinical-stage biotech and a pioneer in targeted oncology. The company is developing a unique VDC (viral-directed particle) platform that delivers drugs directly to cancer cells (e.g., eye cancer). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this breakthrough (VDC) R&D platform (AURA) differentiate it from the average pharma company?
The AKIM Index for the overall market
Aura Biosciences is a biotech company developing a new class of drugs (virus-like conjugates) for the treatment of ocular cancer. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative scientific story fits in with the overall economic trends affecting the healthcare sector.
